Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice
Open Access
- 7 November 2012
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (4) , 879-889
Abstract
Background Cisplatin is an effective anti-neoplastic drug, but its clinical use is limited due to dose-dependent nephrotoxicity. The majority of cisplatin-treated patients develop hypomagnesaemia, often associated with a reduced glomerular filtration rate (GFR), polyuria and other electrolyte disturbances. The aim of this study is to unravel the molecular mechanism responsible for these particular electrolyte disturbances. Methods Two groups of 10 mice were injected intraperitoneally three times, once every 4 days, with cisplatin (5 mg/kg body weight,) or vehicle. Serum and urine electrolyte concentrations were determined. Next, renal mRNA levels of distal convoluted tubule (DCT) genes epithelial Mg2+ channel TRPM6, the Na+-Cl− cotransporter (NCC), and parvalbumin (PV), as well as marker genes for other tubular segments were measured by real-time qPCR. Subsequently, renal protein levels of NCC, PV, aquaporin 1 and aquaporin 2 were determined using immunoblotting and immunohistochemistry (IHC). Results The cisplatin-treated mice developed significant polyuria (2.5 ± 0.3 and 0.9 ± 0.1 mL/24 h, cisplatin versus control, P < 0.05), reduced creatinine clearance rate (CCr) (0.18 ± 0.02 and 0.26 ± 0.02 mL/min, cisplatin versus control, P < 0.05) and a substantially reduced serum level of Mg2+ (1.23 ± 0.03 and 1.58 ± 0.03 mmol/L, cisplatin versus control, P < 0.05), whereas serum Ca2+, Na+ and K+ values were not altered. Measurements of 24 h urinary excretion demonstrated markedly increased Mg2+, Ca2+, Na+ and K+ levels in the cisplatin-treated group, whereas Pi levels were not changed. The mRNA levels of TRPM6, NCC and PV were significantly reduced in the cisplatin group. The expression levels of the marker genes for other tubular segments were unaltered, except for claudin-16, which was significantly up-regulated by the cisplatin treatment. The observed DCT-specific down-regulation was confirmed at the protein level. Conclusions The present study identified the DCT as an important cisplatin-affected renal segment, explaining the high prevalence of hypomagnesaemia following treatment.Keywords
This publication has 56 references indexed in Scilit:
- Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancerJournal of Clinical Investigation, 2011
- Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced NephrotoxicityClinical Pharmacology & Therapeutics, 2009
- Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and NitrotyrosineToxicologic Pathology, 2009
- Cisplatin Nephrotoxicity: A ReviewThe American Journal of the Medical Sciences, 2007
- Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell deathAmerican Journal of Physiology-Cell Physiology, 2005
- Urinary 28-kD Calbindin-D as a New Marker for Damage to Distal Renal Tubules Caused by Cisplatin-Based ChemotherapyUrologia Internationalis, 1996
- Renal toxicity of cancer chemotherapeutic agents in childrenCurrent Opinion in Pediatrics, 1995
- Distal nephrotoxicity of cisplatin demonstrated by urinary kallikrein excretion and morphological study in ratsToxicology, 1991
- Modulation of cis‐diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3‐isobutyl‐1‐methylxanthine in sensitive and resistant human ovarian carcinoma cellsInternational Journal of Cancer, 1991
- Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum CompoundsNature, 1972